MYOS Corp Stock Rating Reaffirmed by Zacks (MYOS)
MYOS Corp (NASDAQ:MYOS)‘s stock had its “outperform” rating reiterated by Zacks in a note issued to investors on Thursday. They currently have a $20.00 target price on the stock. Zacks‘s target price indicates a potential upside of 40.35% from the stock’s previous close.
Zacks’ analyst wrote, “On August 14, 2014, MYOS Corporation announced financial results for the second quarter of 2014. The company recorded net sales of approximately $1.7 million, which was right in line with our expectations, compared to $0.7 million in the corresponding quarter in 2013. Net loss for the quarter was $1.0 million, or $0.34 per share. The company announced a number of milestones this quarter, with perhaps the most important being positive top-line results from the clinical study of Fortetropin showing muscle building activity of the compound in modestly resistance trained male subjects. We continue to rate the stock a Buy, and believe that the positive clinical results will have many positive ramifications for the company. “
MYOS Corp (NASDAQ:MYOS) traded down 3.51% on Thursday, hitting $13.7505. 14,252 shares of the company’s stock traded hands. MYOS Corp has a 52 week low of $6.00 and a 52 week high of $16.85. The stock’s 50-day moving average is $14.10 and its 200-day moving average is $11.93. The company’s market cap is $40.1 million.
MYOS Corp (NASDAQ:MYOS) last posted its quarterly earnings results on Thursday, August 14th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by $0.14. The company had revenue of $1.68 million for the quarter.
MYOS Corporation is engaged in the discovery, development and commercialization of therapeutic products, nutritional supplements and other technologies to improving the health and performance of muscle tissue.
To view Zacks’ full report, visit Zacks’ official website.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.